| __timestamp | Amicus Therapeutics, Inc. | Iovance Biotherapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 47624000 | 2704597 |
| Thursday, January 1, 2015 | 76943000 | 15470000 |
| Friday, January 1, 2016 | 104793000 | 28037000 |
| Sunday, January 1, 2017 | 149310000 | 71615000 |
| Monday, January 1, 2018 | 270902000 | 99828000 |
| Tuesday, January 1, 2019 | 286378000 | 166023000 |
| Wednesday, January 1, 2020 | 308443000 | 201727000 |
| Friday, January 1, 2021 | 272049000 | 259039000 |
| Saturday, January 1, 2022 | 276677000 | 294781000 |
| Sunday, January 1, 2023 | 152381000 | 344077000 |
Unleashing the power of data
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Amicus Therapeutics, Inc. and Iovance Biotherapeutics, Inc. have demonstrated contrasting trajectories in their R&D investments. From 2014 to 2023, Amicus Therapeutics increased its R&D spending by over 220%, peaking in 2020. However, a notable decline occurred in 2023, with a 45% drop from its 2020 high. In contrast, Iovance Biotherapeutics exhibited a steady upward trend, with a remarkable 1,200% increase in R&D expenses over the same period, culminating in 2023. This divergence highlights the strategic differences between the two companies, with Iovance's consistent growth reflecting a robust pipeline strategy. As the biotech landscape evolves, these spending patterns may offer insights into future breakthroughs and market leadership.
Research and Development: Comparing Key Metrics for Eli Lilly and Company and Amicus Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Amgen Inc. and Iovance Biotherapeutics, Inc.
Research and Development Expenses Breakdown: BioMarin Pharmaceutical Inc. vs Amicus Therapeutics, Inc.
R&D Insights: How Exelixis, Inc. and Amicus Therapeutics, Inc. Allocate Funds
Grifols, S.A. or Iovance Biotherapeutics, Inc.: Who Invests More in Innovation?
Comparing Innovation Spending: CymaBay Therapeutics, Inc. and Amicus Therapeutics, Inc.
Research and Development Investment: Apellis Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc.
Analyzing R&D Budgets: CRISPR Therapeutics AG vs Iovance Biotherapeutics, Inc.
R&D Spending Showdown: Perrigo Company plc vs Amicus Therapeutics, Inc.
Research and Development Expenses Breakdown: Amicus Therapeutics, Inc. vs Geron Corporation
R&D Spending Showdown: Amicus Therapeutics, Inc. vs Galapagos NV
Who Prioritizes Innovation? R&D Spending Compared for Protagonist Therapeutics, Inc. and Iovance Biotherapeutics, Inc.